ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma

Grant

Awarded By

Total Award Amount

  • 52467.00

    • Direct Costs

  • 40359.00

    • Sponsor Award Id

    • Contributor

  • Aman Wadhwa   Investigator  
  • Ana Xavier   Investigator  
  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Gregory Friedman M.D.   Principal Investigator  
  • Jamie Aye   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Laura Metrock   Investigator  
  • Matthew Kutny M.D.   Investigator